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AKT   v-akt Murine Thymoma Viral oncogene homolog 
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MGMT   O-6-Methylguanine-DNA Methyltransferase 
MLPA   Multiplex Ligation-dependent Probe Amplification 
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MTOR   Mechanistic Target of Rapamycin (serine/threonine kinase) 
MYC   v-myc Myelocytomatosis Viral Oncogene homolog 
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PIAS   Protein Inhibitors of Activated STATs 
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PLCG1  Phospholipase C, Gamma 1 
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Abstract: 
Central Nervous System (CNS) Neoplasms are characterized by their cell of 
origin and their histopathological features. Tumors of glial cell origin (Gliomas) are the 
most frequent, with Glioblastoma Multiforme (GBM) rising as the most common. GBM 
tumors of grade IV accordingly with the World Health Organization (WHO), are 
generally lethal, with a median survival time of 4.9 months, and their most striking 
histopathological features are the high degree of vascularization and necrosis. 
 The most common genetic alterations in GBM are the amplification, 
overexpression and mutation of the EGFR gene, and the deletion of the long arm of 
chromosome 10, where, among others, the PTEN gene is located. These genes are 
related, respectively, with the activation and inhibition of pathways like the MAPK 
cascade, the PIP-mediated signaling and STAT signaling which are involved in cellular 
proliferation and inhibition of apoptosis. Deregulation of these pathways renders them 
the logical target for inhibition of growth and proliferation of tumoral cells, and some 
anti-EGFR therapies have been tried, but with relatively poor success. 
 The goal of this work is to analyse the genetic expression of the genes that 
make up the EGFR-activated signaling pathways in gliomas, and identify those 
molecules where targeted intervention would make sense in such a way that cellular 
proliferation would cease, and differentiation and apoptosis would be induced. 
 Tumor samples (n=100) were characterized by Multiplex Ligation-dependent 
Amplification (MLPA) and Chromosomal Comparative Genomic Hybridization (cGGH). 
Further analysis of tumors samples (n=15) was done by using Gene Expression Arrays 
GeneChip® HuGene 1.0ST and data analysis softwares Partek Genomics Suite and 
Ingenuity Pathway Analysis, in order to determine the expression values of the various 
genes that make up the EGFR-activated signaling pathways. This allowed us to identify 
a particular pathway that appears to have its components constantly overexpressed, 
the STAT signaling pathway, mainly through the STAT3 gene. 
 The STAT3 protein is activated by various receptors and is implicated in 
tumorigenesis and immune evasion, and as such, may be a suitable target for anti-
neoplasic therapies. 
 
Key-words: Glioma, EGFR, STAT3. 
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Resumo  
Os tumores do Sistema Nervoso Central (SNC) são caracterizados pelo tipo de 
célula original e características histopatológicas. Representam cerca de 1,2% das 
neoplasias diagnosticadas em 2002 (Parkin et al., 2005). Os tumores de origem glial 
(Gliomas) são os mais comuns, destacando-se entre eles o Glioblastoma Multiforme 
(GBM) que representa cerca de 15% das neoplasias intracranianas.  
Os tumores GBM de grau IV segundo a Organização Mundial de Saúde (OMS), 
são geralmente letais, com um tempo médio de sobrevida de 4,9 meses, e são 
caracterizados histopatologicamente pelo seu elevado grau de vascularização e 
necrose (Louis et al., 2007). Apesar de indistinguíveis a nível histopatológico, estas 
neoplasias podem ser subdivididas em GBM primário (pGBM) e secundário (sGBM). 
Estes grupos distinguem-se pelo processo de progressão e pelas características 
genéticas. Os pGBMs apresentam as características histopatológicas de GBM, 
aquando do seu diagnóstico inicial, enquanto que os sGBMs são caracterizados por 
uma progressão a partir de neoplasias de grau inferior (Ohgaki et al., 2005). 
As alterações genéticas mais comuns em tumores GBM (com diferentes 
incidências entre os subtipos) são o ganho de cópias do cromossoma 7 com 
amplificação em 7p12 [onde se situa, entre outros, o gene EGFR (Epidermal Growth 
Factor Receptor)], a deleção do braço longo do cromossoma 10 [onde se situa, entre 
outros, o gene PTEN (Phosphatase and Tensin Homologue)] e a mutação no gene 
TP53 (Nicholas et al., 2006). 
Este tipo de alterações tem impacto directo na activação e regulação de várias 
vias de sinalização envolvidas no controlo da proliferação celular, no controlo do ciclo 
celular e na indução da apoptose. Destas vias, as mais relevantes na caracterização 
dos GBM são as vias relacionadas com os genes Rb, TP53 e EGFR (The Cancer 
Genome Atlas (TCGA), 2008). 
A via TP53/MDM2/p14ARF é responsável pelo controlo da integridade do DNA 
antes da divisão celular. Em tumores GBM é comum haver alteração do gene TP53 
(com inibição da actividade da proteína TP53), o que permite a proliferação celular 
neoplásica. Além da alteração directa da proteína TP53, também é comum ocorrer a 
sobreexpressão de MDM2 (inibidor de TP53) e a subexpressão de p14ARF (inibidor de 
MDM2) (Ohgaki et al., 2007). 
A via associada ao gene Rb é responsável pelo controlo da progressão do ciclo 
celular de G1 para S. Em tumores GBM é comum a subexpressão do gene Rb e de 
p16INK4A (ambos inibidores da progressão G1-S), o que favorece a progressão 
desregulada do ciclo celular (Ohgaki et al., 2007). 
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O gene EGFR codifica um receptor com actividade cinásica de tirosinas (RTK – 
Receptor Tyrosine Kinase) da família ErbB, que é responsável pela transdução de 
sinal de vários factores de crescimento. A activação deste receptor pelos seus 
ligandos (e.g. EGF, HB-EGF e TGF-α, entre outros), provoca a homodimerização de 
EGFR ou a sua heterodimerização com outro membro da família ErbB, levando a uma 
autofosforilação de resíduos na extremidade –COOH da proteína, o que a torna capaz 
de fosforilar moléculas das vias de sinalização das MAP cinases, do Fosfatidilinositol-
3,4,5-Fosfato (PIP3) e das STATs (Sebastian et al., 2006). Quando activadas, estas 
vias levam a um aumento generalizado da capacidade de proliferação das células 
neoplásicas e, consequentemente, da tumorigénese. Em tumores GBM, é comum 
observar desregulação destas vias por sobreexpressão dos seus activadores (e.g. 
EGFR) e/ou por subexpressão dos seus reguladores (e.g. PTEN) (Ohgaki et al., 2007). 
O tratamento de tumores GBM consiste na remoção cirúrgica da área afectada, 
seguida de radioterapia. A temozolamida (um agente alquilante) (Stupp et al., 2009), 
pode ser adicionada e, em certos casos, aumenta a sobrevida para 14,6 meses.  
O reconhecimento da importância do EGFR no processo tumorigénico em 
gliomas, tornou-o o alvo óbvio na busca de novas terapias anti-neoplásicas e no 
aumento da sobrevida (Kuan et al., 2001; Kari et al., 2003). Com esse intuito, foram 
tentadas várias estratégias para impedir a activação das vias de sinalização activadas 
por EGFR (Halatsch et al., 2006). Uma das estratégias baseia-se no impedimento 
físico do reconhecimento de ligandos e de dimerização do receptor e é representada 
pelo anticorpo monoclonal Cetuximab (Li et al., 2005; Halatsch et al., 2006), que tem, 
no entanto, demonstrado fracos resultados em ensaios clínicos (Neyns et al., 2009). 
Uma outra estratégia baseia-se no bloqueio da actividade cinásica do receptor, 
utilizando inibidores moleculares da cinase de tirosinas (TKIs) (Halatsch et al., 2006; 
Omuro et al., 2007), que têm demonstrado igualmente fracos resultados na inibição da 
sinalização mediada pelo EGFR (Lassman et al., 2005).  
O facto de as vias de sinalização activadas pelo EGFR serem partilhadas por 
outras RTKs pode explicar, em parte, o fraco desempenho destas estratégias 
terapêuticas. O objectivo deste trabalho consiste em analisar as vias de sinalização 
activadas pelo EGFR com base na expressão génica dos seus constituintes, e 
identificar potenciais alvos nos quais uma intervenção dirigida faça sentido de modo a 
bloquear a proliferação celular e induzir apoptose e diferenciação nestas neoplasias. 
Para alcançar este objectivo analisámos cerca de 100 gliomas com diferentes 
alterações genéticas previamente identificadas por Chromosomal Comparative 
Genomic Hybridization (cCGH) e avaliámos nestes casos a presença de possíveis 
mutações no gene EGFR por Multiplex Ligation-dependent Probe Amplification 
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(MLPA). Dentro deste grupo de gliomas, determinámos os perfis de expressão de 15 
casos, usando os Arrays de expressão génica GeneChip® HuGene 1.0ST da 
Affymetrix, a partir de extractos de RNA total. Os perfis de expressão dos diferentes 
grupos de amostras foram depois comparados com um controlo de córtex cerebral 
normal usando o software Partek Genomics Suite. A utilização deste software permitiu-
nos quantificar as diferenças de expressão génica entre os diferentes subgrupos de 
tumores e o córtex cerebral normal. Estes valores foram depois inseridos no software 
Ingenuity Pathway Analysis (IPA), que origina vias de sinalização canónicas e redes 
de interacções entre genes sobrepondo-lhes os valores de expressão de cada gene 
envolvido.  
A partir dos dados obtidos pelo software IPA, foi possível determinar o padrão 
de expressão dos vários componentes das vias de sinalização activadas pelo EGFR 
nos vários subgrupos de tumores:  
- 5 GBM com ganho de cromossoma 7 e amplificação em 7p12; 
- 3 GBM com ganho de cromossoma 7; 
- 1 Ganglioglioma Anaplásico com ganho de cromossoma 7 e respectiva linha celular; 
- 2 Gliomas (um GBM e um Oligodendroglioma Anaplásico) com amplificação em 
8q24; 
- 1 GBM com ganho de cromossoma 7 e amplificação de 4q12; 
- 3 Linhas celulares com diferentes alterações genéticas. 
À excepção dos dois casos com amplificação em 8q24 (onde se situa, entre 
outros, o gene c-Myc), todos os outros tumores e linhas celulares demonstram uma 
sobreexpressão dos componentes da via STAT (Signal Transducers and Activators of 
Transcription). Nas vias de sinalização PIP e das MAP cinases não se verificam 
alterações substanciais que nos indiquem que estas possam ser preferencialmente 
utilizadas na sinalização activada por EGFR. 
A via de sinalização STAT, particularmente a molécula STAT3, é directamente 
activada pelo receptor EGFR, por fosforilação de um resíduo de tirosina na posição 
705, levando à homo- ou heterodimerização (com STAT1) e, consequentemente, a um 
aumento da actividade transcricional, mediada por STAT, de vários genes (Dauer et 
al., 2005), entre os quais o gene c-Myc. Propomos que a activação preferencial da via 
STAT permita à célula tumoral aumentar a expressão de c-Myc, pelo que quando a 
sua expressão está aumentada por outras razões (como a que resulta da amplificação 
do seu locus) diminua a pressão selectiva para que a via STAT tenha os seus 
componentes sobreexpressos (como se verifica nos casos com amplificação de 8q24). 
 A presença de STAT3 activado, em gliomas, foi demonstrada (Abou-Ghazal et 
al., 2008) e o seu papel na tumorigénese (Abou-Ghazal et al., 2008) e na 
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imunosupressão (Kortyleswki et al., 2008) foi realçado, tornando-a um alvo terapêutico 
óbvio, tendo já sido tentadas várias abordagens de inibição desta molécula, que 
incluem o uso de RNA de interferência (Konnikova et al., 2003; Li et al., 2009), 
oligonucleótidos inibitórios (Gu et al., 2008), fosfopéptidos (Shao et al., 2003) e 
inibidores moleculares (Fuh et al., 2009). 
 O facto de STAT3 estar sobreexpresso na maioria dos casos analisados, da 
sua activação estar comprovada em gliomas de alto grau, de estar envolvido no 
processo tumorigénico e de imunossupressão, e de também poder ser activado por 
vários outras RTKs e não-RTKs que não o EGFR, leva-nos a propor que em gliomas a 
via STAT3 é a via de sinalização preferencialmente activada por EGFR, entre outros. 
 
Palavras-chave: Glioma, EGFR, STAT3 
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Introduction 
 Central Nervous System (CNS) Neoplasms are a result of an abnormal growth of 
cells within the CNS, and can be of various types, as determined by their cell of origin and 
histopathological features. The World Health Organization (WHO) classifies and grades CNS 
neoplasms into four grades, Grade 1 being the less severe and Grade 4 the most severe 
(Louis et al., 2007).  
 CNS Neoplasms account for 1.7% of all neoplasms that were diagnosed in 2002, and 
around 2.1% of cancer related fatalities (Parkin et al., 2005). One of the most distinctive 
features of CNS neoplasms is their lethality and short survival period. The most common 
CNS tumor, Glioblastoma Multiforme (GBM), accounting for 12-15% of intracranial 
neoplasms, and 60-75% of astrocytic neoplasms, is a WHO Grade 4 glioma, with a median 
survival time of 4.9 months (Ohgaki et al., 2005). This neoplasm is defined by a typically 
astrocytic differentiation, and its histopathological 
features include nuclear atypia, cellular pleomorphism, 
mitotic activity, vascular thrombosis, microvascular 
proliferation and necrosis (Louis et al., 2007). It affects 
mainly adults and it emerges mostly in the white 
subcortical matter of the brain hemispheres (Louis et 
al., 2007) (Figure 1). 
 GBM can be divided into two classes, 
Primary Glioblastoma (pGBM), accounting for 
roughly 95% of GBM cases, and Secondary Glioblastoma (sGBM), around 5% of GBM 
cases. Although they are histopathologically indistinguishable, they do have several 
differences. The median age of diagnosis of pGBM is 62 years, with a median survival time 
of 4.7 months, unlike sGBM, in which the median age of diagnosis is 45 years, with a median 
survival time of 7.8 months (mostly due to age difference between the groups) (Ohgaki et al., 
2005). Another distinction that can be made between pGBM and sGBM is the way they both 
progress. sGBM progresses from less severe lesions (like a low-grade astrocytoma), unlike 
pGBM, which is primarily diagnosed as such, without evidence of previous lesions. Also, their 
genetic modifications are somewhat different, EGFR (Epidermal Growth Factor Receptor) 
amplification and overexpression being most common in pGBM (40% and >60% in pGBM, 
8% and <10% in sGBM), and TP53 mutation appearing mostly in sGBM (28% in pGBM, 65% 
in sGBM). One feature that seems to be similar in both types of GBM is Loss of 
Heterozygosity (LOH) in 10q (70% of pGBM and 63% of sGBM) (Nicholas et al., 2006) 
(Figure 2). 
Figure 1. Glioblastoma Multiforme in a transverse 
cross section of the adult brain.    
(http://www.neuropathologyweb.org/chapter7/chapter
7bGliomas.html) 
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Some of the most defining genetic modifications in GBM have direct impact on 
various signaling pathways. The most studied signaling pathways in GBM are related with 
the TP53, Rb and EGFR genes (Louis et al., 2007; The Cancer Genome Atlas Research 
Network (TCGA), 2008).  
The TP53/MDM2/p14ARF pathway is responsible for maintaining DNA integrity prior to 
cell division. TP53 (a tumor suppressor gene, coding for the p53 protein) is one of the most 
important and tightly regulated genes of the cell, having the ability to block cell division if 
there is any type of damage in the genome (Lodish et al., 2008). In most sGBM (65%), TP53 
gene is altered (57% of mutations located in codons 248 and 273), this event occurring less 
frequently in pGBM (30%). Direct modifications of the TP53 gene that disable its activity are 
enabling of neoplastic cell proliferation. Beside the direct modifications on the TP53 gene, 
GBM tumors also have other mechanisms of disabling its activity. For instance, MDM2 
(Murine Double Minute 2, an inhibitor of p53) is amplified in 31% of pGBM, which leads to 
increased capacity of the cell to inhibit p53, and hence, increased capacity of cell division. 
There is yet another way of the cell to decrease p53 activity, and this is achieved by 
deregulation of the MDM2 protein inhibitor, p14ARF. The p14ARF gene is underexpressed in 
76% of GBM (either by homozygous deletion or promoter methylation) (Ohgaki et al., 2007).  
Thus, the neoplastic cell has various features enabling blockage p53 regulation, 
either by modification of the TP53 gene (mainly in sGBM) or by overexpressing of its inhibitor 
MDM2 (mainly pGBM), or even by underexpressing MDM2’s inhibitor, p14ARF. 
The Rb1 (Retinoblastoma) protein regulates progression through the cell cycle, 
mainly the G1-S transition. In a normal cell, a CDK4/ciclinD1 complex phosphorylates the 
Figure 2. Differences between pGBM and sGBM (adapted from Ohgaki et al., 2007). 
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Rb1 protein, allowing the release of the E2F transcription factor which regulates several 
genes responsible for the G1-S transition. p16INK4A is the inhibitor of CDK4, and therefore, the 
inhibitor of the progression through the cell cycle (Lodish et al., 2008). In GBM this pathway 
is usually deregulated by either the deregulation of the p16INK4A gene, the underexpression of 
the RB1 gene, or by both events. The p16INK4A gene is deregulated by either homozygous 
deletion, or by promoter methylation, and is most common in pGBM. RB1 gene 
underexpression is achieved in GBM by promoter methylation, an event which occurs in 43% 
of sGBM and 14% of pGBM (Ohgaki et al., 2007).  
In a similar way to the p53 deregulation described above, Rb1 deregulation may 
come by either direct inhibition of the RB1 gene, or by modification of other members of the 
pathway that inhibit cell cycle progression. 
One of the most defining features of GBM is the amplification, overexpression and 
mutation of the EGFR gene, and the prevalent activation of the EGFR family (TCGA, 2008). 
This gene occupies roughly 200 kb of the 7p12 region in chromosome 7 [which is amplified in 
approximately 40% of GBM (Olson et al., 2009)] and is composed by 28 exons (Reiter et al., 
2001). A common feature in GBM is that EGFR amplification is commonly accompanied by 
various mutations. The most common mutation is EGFRvIII [accounting for roughly 60% of 
mutations (Nicholas et al., 2006)] present in 54% of cases with amplification of the EGFR 
gene (Olson et al., 2009). This mutation is defined by an inframe deletion of exons 2 through 
7, leading to a truncated protein lacking the extracellular binding domain. This truncated 
version of the EGFR is constitutively active, leading to increased activation of downstream 
signaling pathways (Ohgaki et al., 2007).  
The EGFR protein is a receptor tyrosine kinase (RTK) of the ErbB family. This 
receptor can directly translate extracellular stimulus (by binding of the EGFR ligands, like 
EGF, HB-EGF, TGFα and others, and dimerization with another member of the ErbB family), 
into phosphorylation of downstream targets of the Ras/MAPK cascade signaling pathway, 
the PIP signaling pathway and the STAT signaling pathway (Oda et al., 2005; Sebastian et 
al., 2006) (Figure 3).  
The mitogen-activated protein kinase (MAPK) cascade is involved in a variety of 
cellular functions such as growth, proliferation, differentiation, migration and apoptosis 
(Lodish et al., 2008; Zohrabian et al., 2009). These pathways rely on the sequential 
phosphorylation of several proteins, beginning in the activation of Ras [a known oncogene, 
mutated in 2% of GBM (TCGA, 2008)] and ending in the activation of various transcription 
factors (c-Jun and c-Fos) that regulate expression of cell-cycle progression and 
differentiation related proteins (elegantly reviewed in Lodish et al., 2008 Chapters 14.3 and 
14.4).  
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Figure 3. EGF receptor mediated signaling pathway overview (www.sigmaaldrich.com). 
Phosphatidylinositol (PIP) signaling is one of the most important pathways in the cell. 
It regulates multiple biological events such as apoptosis, metabolism, cell proliferation and 
cell growth (Blanco-Aparicio et al., 2007). RTKs can signal through PIP either by activation of 
the PIP3/DAG or PI3K pathways. Both these pathways lead to activation of Akt or mTOR 
proteins and thus to cell proliferation (as reviewed in Lodish et al., 2008 Chapter 14.5, and in 
Blanco-Aparicio et al., 2007). Regulation of the PI3K pathway is accomplished by the PTEN 
(Phosphatase and Tensin homolog) protein. The PTEN gene is located on the long arm of 
chromosome 10, which loss is a common event in GBM (70% of pGBM and 63% of sGBM). 
In a normal cell PTEN removes phosphate from PIP3 (a key molecule in PIP signaling), 
inhibiting PIP downstream signaling. If PTEN is lost, PIP signaling can occur almost 
constitutively, promoting cell survival and proliferation (Lodish et al., 2008). 
STAT (Signal Transducer and Activator of Transcription) proteins are a family of 
transcription factors that are activated (phosphorylated) as a response to extracellular 
stimulus of various receptors like RTKs, cytokine receptors (like IL6R, OSMR) and others 
(Caló et al., 2003; Lodish et al., 2008 Chapter 14.2). Activation of the STAT transcription 
factors can lead to events such as differentiation, proliferation, cell survival, apoptosis and 
angiogenesis. STAT proteins can be divided into two groups, according to their specific 
functions. One group, made up of STAT2, STAT4 and STAT6, is activated by cytokines and 
plays a distinct role in T-Cell differentiation and IFNγ signaling (Caló et al., 2003). The other 
group, made up of STAT1, STAT3 and STAT5, is activated by various ligands, and plays a 
role in controlling cell-cycle progression and apoptosis (Bromberg, 2002).  
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STAT phosphorylation can be mediated either by JAK (Janus Kinase) (Wilks, 2008), 
Non-RTK proteins like Src (Silva, 2004) or directly by RTKs like EGFR (Coffer et al., 1995; 
Ihle, 1996). STAT signaling is regulated by the SOCS proteins (Supressor of cytokine 
signaling), PIAS proteins (Protein Inhibitor of Activated STATs) and Protein tyrosine 
phosphatases (Brantley et al., 2008a). SOCS proteins attenuate STAT signaling through 
inhibition of upstream JAK activation, in a classical feedback loop. PIAS are constitutively 
expressed proteins that mediate transcriptional repression by interfering with STAT 
transcription factors ability to bind DNA. Protein tyrosine phosphatases, like PTPRD (Protein 
Tyrosine Phophatase Receptor-type D) (Veeriah et al., 2009) inhibit STAT signaling by 
removing phosphate from STAT proteins, rendering them inactive. 
STAT3 activation has been linked to GBM (Brantley et al., 2008a), either by 
constitutive activation of STAT3 protein or by loss of its inhibitors, like PIAS-3 (Brantley et al., 
2008b). STAT3 regulates transcription of several genes, like c-Myc (Dauer et al., 2005; 
Bowman et al, 2009), EGFR (Dauer et al., 2005) and other genes like Bcl-2, Bcl-x and mcl-1, 
which are related to inhibition of apoptosis (Rahaman et al., 2002). 
The treatment of GBM is based heavily upon radiation therapy and adjuvant 
temozolomide followed by surgical resection of the tumor mass increasing progression-free 
survival (PFS) to 14.6 months (Stupp et al., 2005; Olson et al., 2009). 
Temozolomide is a cytostatic prodrug that is rapidly absorbed by oral administration, 
is able to cross the blood-brain barrier and is spontaneously hydrolyzed to the active 
metabolite methyltriazeno-imidazole-carboxamide (MTIC). In the cell, MTIC methylates DNA 
at several positions, of which methylation at the O6 positition of a guanine is regarded as 
fatal for the cell (Friedman et al., 2000). The methyl group at O6 can be removed by the DNA 
repair enzyme MGMT. Methylation of the MGMT gene promoter in GBM has been linked with 
an increase of PFS to 21.7 months (Hegi et al., 2005). 
Altough improved with the use of chemotherapy and adjuvant temozolomide, 
prognosis of GBM still remains dismal. Alternative therapies have been attempted with 
various results (Omuro et al., 2007). Some of these therapies target the EGFR protein. As 
mentioned previously, EGFR overexpression and amplification, in league with the EGFR 
protein’s ability to activate various pathways related to oncogenesis, make it a natural target 
for cancer therapy (Kuan et al., 2001; Kari et al., 2003). 
Attempts of targeting EGFR as a means to induce tumor regression have been made, 
mainly by two approaches (Halatsch et al., 2006).  
The first approach is based upon the inhibition of the receptors ability to either bind its 
ligands or to dimerize. This type of inhibition may be accomplished by the use of antibodies 
like Cetuximab and other EGFR specific antibodies (Halatsch et al., 2006). Cetuximab 
physically inhibits binding of EGFR ligands and also prevents EGFR conformational 
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modifications that allow it to dimerize. (Li et al., 2005).  Cetuximab has had promising results 
in animal models (Martens et al., 2008) but as shown limited potential in phase-II clinical 
trials (Neyns et al.,2009). 
The second approach is based upon the inhibition of the receptors ability to 
phosphorylate downstream targets, that is, inhibition of its Tyrosine Kinase domain. This may 
be accomplished by Tyrosine Kinase Inhibitors (TKIs) such as Erlotinib and Gefitinib 
(Halatsch et al., 2006). Both Erlotinib and Gefitinib inhibit the TK domain of EGFR by 
selectively binding its ATP-binding position, thus rendering it inactive (Omuro et al., 2007). 
Regrettably, these compounds have failed at showing significant inhibition of EGFR-
mediated signaling in GBM (Lassman et al., 2005). An effort has been made to explain why 
TKIs are unsuccessful. Conflicting theories have come up in regard to EGFR copy number 
and EGFRvIII status as markers of sensitivity (Mellinghoff et al., 2005) or resistance (Learn 
et al., 2004). Also, successful inhibition of EGFR may only diminish downstream signaling 
pathways, because EGFR shares its signaling pathways with many other RTKs and non-
RTKs. Also, PTEN inhibition as been suggested as a marker of increased tumor resistance 
to TKIs (Mellinghoff et al., 2005; Guillamo et al., 2009).  
The dismal prognosis of GBM, allied with the yet relative failure at therapies based 
upon EGFR direct targeting, lead us to suggest that GBM treatment should by targeted at 
intra-cellular points in the EGFR activated pathways. Therefore, the goal of this project is to 
study the signaling pathways activated by EGFR, and by means of gene expression analysis, 
understand if there is any genetic preference to a particular pathway or molecule of a 
pathway, in which targeted therapy would be a valid option. 
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Materials and Methods 
DNA Extraction for Multiplex Ligation-dependent Probe Amplification (MLPA) and 
Chromosomal Comparative Genomic Hybridization (cCGH) 
DNA extraction from frozen glioma tumor samples (n=100) was performed with the 
Proteinase K and Phenol protocol for isolation of High-molecular-weight DNA (Sambrook et 
al., 2001), concentration and purity were determined with NanoDrop ND-1000 
spectrophotometer (NanoDrop Technologies, Wilmington, DE, USA). For MLPA, DNA was 
diluted in Tris-EDTA 1X buffer pH 8.0. For cCGH, DNA was diluted in Tris buffer 1X pH 8.0. 
Chromosomal Comparative Genomic Hybridization 
cCGH analysis was performed from frozen material at the Cytogenetics laboratory – 
CIPM of the Lisbon Portuguese Cancer Institute. cCGH was performed according to the 
method of Kallioniemi (Kallioniemi et al., 1994). Briefly, tumor DNA was labeled with biotin 
16dUTP (Enzo-Roche), and normal reference DNA with digoxigenin-11-dUTP (Enzo-Roche), 
in a standard nick translation reaction. Equal amounts (400ng) of labeled tumor DNA and 
labeled reference DNA were coprecipitated with 15 µg of Cot-1-DNA (Invitrogen) in ethanol. 
After a 3-day hybridization period, fluorescent detection ot the biotin- and digoxigenin-labeled 
DNAs was accomplished by using avidin-FITC (Jackson Immunoresearch) and 
antidigoxigenin rhodamine (Enzo-Roche) antibodies, respectively. Samples were 
counterstained in DAPI in antifade solution (Vector). For image acquisition, an epifluorescent 
microscope (Zeiss Axioplan II) equipped with a cooled CCD Camera (Photomic Science) and 
a triple-band beam splitter and emission filters (Chroma Technology, USA) were used. For 
each tumor, three color images (blue, red and green) were acquired from at least 10 
metaphases. Image analysis was performed using the cCGH analysis software from 
CytoVision System (version 2.51 Applied Imaging, Sunderland Tyne & Wear, UK). A 
simplified overview of this protocol is given in Supplementary Figure S1. 
 
Multiplex Ligation-dependent Probe Amplification (MLPA) 
For EGFR mutational analysis SALSA P315 Kit for EGFR from MRC-Holland was 
used (MRC-Holland, Amsterdam, The Netherlands). This kit includes probes for each of the 
28 exons of the EGFR gene. As a control, this kit also includes 9 probes for different 
chromosomal positions (2q37.3, 3q11.2, 5p13.2, 5q35.3, 7q21.1, 9q31.1, 10q23.3, 12q23 
and 17p13.1). MLPA Protocol was carried out as previously described (Schouten et al., 
2002), using 100ng of DNA for each normal control and tumor sample. 3 µL of the amplified 
sample product was analyzed using ABI 3130 Genetic Analyzer and as an internal size 
standard the Genescan 500 LIZ (ABI 4322682). Successful ligation reaction and 
identification of samples with insufficient amount of DNA were verified using MLPA’s internal 
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ligation-independent probes. Data analysis was carried out with the MRC-Coffalyser version 
8.0. Ratios were calculated using the Tumor Analysis LS method in MRC-Coffalyser V8. 
Tumor Analysis LS is a direct analysis method which performs slope correction in all probes 
and then compares each individual probe peak height in a sample (which is related to the 
relative quantity of the probe target in the sample) to its counterpart in a normal reference 
control, establishing ratios between them: Homozygous loss of a particular probe was 
considered when ratios were 0; Heterozygous loss was considered when ratios were 
between 0,3 and 0,7; Normal status was considered when ratios were between 0,7 and 1,3; 
Gain was considered when ratios were between 1,3 and 1,7; Amplification was considered if 
ratios were above 2,5. A simplified overview of this protocol is given in Supplementary Figure 
S2. 
Microarray Analysis 
Human cerebral cortex total RNA was purchased from Clontech (Mountain View, CA, 
USA), consists of a pool of cerebral cortex RNA obtained from 10 individuals who died from 
sudden death, and was used as normal baseline reference for microarray experiments. 
Total RNA was extracted from tumor samples, using the RNeasy Lipid Tissue Mini Kit 
(Qiagen, Hilden, Germany). Concentration and purity was determined with NanoDrop ND-
1000 spectrophotometer (NanoDrop Technologies, Wilmington, DE, USA), and integrity was 
confirmed using an Agilent 2100 Bioanalyzer with a RNA 6000 Nano Assay (Agilent 
Technologies, Palo Alto, CA, USA). Samples were selected if they had more than 100 ng of 
RNA and a RNA Integrity Number (RIN) larger than 7. RNA was processed for use on 
Affymetrix (Santa Clara, CA, USA) GeneChip® HuGene 1.0 ST Arrays, according to the 
manufacturer’s Whole Transcript Sense Target Labeling Assay, at the Affymetrix Core 
Facility located in the Gulbenkian Institute of Science. Briefly, 100 ng of total RNA containing 
spiked in Poly-A RNA controls (GeneChip® Expression GeneChip® Eukaryotic Poly-A RNA 
Control Kit; Affymetrix) were used in a reverse transcription reaction (GeneChip® WT cDNA 
Synthesis Kit; Affymetrix) to generate first-strand cDNA. After second-strand synthesis, 
double-stranded cDNA was used in an in vitro transcription (IVT) reaction to generate cRNA 
(GeneChip® WT cDNA Amplification Kit; Affymetrix). 10 µg of this cRNA were used for a 
second cycle of first-strand cDNA synthesis (GeneChip® WT cDNA Synthesis Kit; 
Affymetrix). 5.5 µg of single stranded cDNA were fragmented and end-labeled (GeneChip® 
WT Terminal Labeling Kit; Affymetrix). Size distribution of the fragmented and end-labeled 
cDNA, respectively, was assessed using an Agilent 2100 Bioanalyzer with a RNA 6000 Nano 
Assay. 5 µg of end-labeled, fragmented cDNA were used in a 100-µl hybridization cocktail 
containing hybridization controls. 80 µl of mixture were hybridized on arrays for 17h at 45°C. 
Standard post hybridization wash and double-stain protocols (FS450_0007; GeneChip® 
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HWS kit, Affymetrix) were used on an Affymetrix GeneChip® Fluidics Station 450. Arrays 
were scanned on an Affymetrix GeneChip® scanner 3000 7G. A simplified overview of this 
protocol is given in Supplementary Figure S3. 
 
Gene Expression Analysis 
RMA Background Correction, Quantile Normalization, Log2 Transformation and 
Median Polish Summarization were performed on the initial microarray data with the Partek 
Genomics Suite (GS) software (Partek Inc. St. Louis, MO). To determine gene expression 
ratios and fold-change between the various samples (Table 2) and the normal cerebral brain 
cortex control, one-way ANOVA statistical analysis was performed with Partek GS. ANOVA, 
or Analysis of Variance, is a parametric test which is used to test differences in means of a 
response variable between different groups. Also, in the context of the ANOVA analysis, 
linear contrasts between the different groups were performed, yielding gene expression 
Ratios and Fold-Change values (FC). Ratios were calculated by the ratio between the Least 
Squares Mean (LS Mean, calculated as the linear combination of the estimated means 
generated by the ANOVA model) of the different groups. Fold-change was determined in a 
similar fashion. Genes identified with a FC over 2 (e.g. overexpressed in sample A vs B) and 
genes with a FC below -2 (e.g. underexpressed in sample A vs B) were then selected for 
gene ontology analysis and EGFR pathway construction 
 
Gene ontology, canonical pathways, and functional network analysis 
Gene ontology, canonical pathways and functional network analysis were performed 
with the Ingenuity Pathway Analysis software (Ingenuity Systems, Redwood City, CA), which 
enables the discovery, visualization and exploration of molecular interaction networks in 
gene expression data. The gene lists identified by ANOVA, containing Genebank accession 
numbers as clone identifiers as well as FC values, were uploaded into the Ingenuity Pathway 
Analysis software. Each clone identifier was mapped to its corresponding gene object in the 
Ingenuity pathway knowledge base. These so-called focus genes were then used as a 
starting point for generating biological networks. A score was computed for each network 
according to the fit of the original set of significant genes. This score reflects the negative 
logarithm of the P that indicates the likelihood of focus genes in a network being found 
together due to random chance. Significance for biological functions were then assigned to 
each network by determining a P for the enrichment of the genes in the network for such 
functions or pathways compared with the whole Ingenuity pathway knowledge base as a 
reference set. Right-tailed Fisher’s exact test was used with α=0.05. The same statistical 
approach was used for gene ontology analysis of the initial gene lists. Molecules in networks 
and canonical pathways were given a color code directly related with their expression value. 
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A molecule is light-green if its expression value is two-fold smaller than in the control (which 
means that particular molecule is underexpressed in the sample set). A molecule is light-red 
if its expression value is two-fold larger than in the control (which means that molecule is 
overexpressed in the sample set). The darker the tone of green or red, the more that 
molecule is respectively under- or overexpressed. A molecule is colored grey if its expression 
value is between these two limits. A molecule is colored white if no information is available in 
regard to its expression. A list with Network shapes (Supplementary Figure S4) and 
Relationship types (Supplementary Figure S5) is given in the Supplementary Data section. 
EGFR Signaling Pathway: 
Along with the IPA EGFR signaling pathways, an EGFR Signaling Pathway adapted 
from the work of Oda et al. (Oda et al., 2005) was also constructed. This group constructed a 
comprehensive pathway for EGFR-mediated signaling based on published scientific papers, 
namely EGFR endocytosis followed by its degradation or recycling, small guanosine 
triphosphatase (GTP-ase)-mediated signal transduction such as mitogen-activated protein 
kinase (MAPK) cascade, phosphatidylinositol polyphosphate (PIP) signaling, cell cycle, and 
G Protein-coupled receptor (GPCR)-mediated transactivation via intracellular Ca2+ signaling. 
Oda’s et al. map was created using CellDesigner (http://celldesigner.org), a software 
package that enables users to describe molecular interactions using a well-defined and 
consistent graphical notation. The data of molecular interactions are stored in Systems 
Biology Markup Language (SBML; http://sbml.org/). They are based on the molecular 
interactions documented in 242 papers accessible from PubMed 
(http://www.ncbi.nlm.nih.gov). It comprises 211 reactions (131 state transitions, 34 
transportations, 32 associations, 11 dissociations, 2 truncations and 1 unknown transition) 
and 322 species (202 proteins, 3 ions, 21 simple molecules, 73 oligomers, 7 genes and 7 
mRNAs). A ‘species’ is defined by SBML as ‘an entity that takes part in reactions’ and it is 
used to distinguish the different states that are caused by enzymatic modification, 
association, dissociation, and translocation. In our EGFR Signaling Pathway adapted from 
Oda’s et al. work, we included the GTP-ase mediated signal transduction (MAPK cascade), 
the PIP signaling and also STAT signaling. Like in the Ingenuity Pathway Analysis, we also 
colored the individual molecules in a direct relation with their expression values. So, 
molecules colored red had a two-fold expression value above the normal control 
(overexpressed), green colored molecules had a two-fold expression value below the normal 
control (underexpressed), and as in the IPA pathways the darker the tone of green or red, 
the more that molecule is respectively under- or overexpressed. White colored molecules 
had expression values between these limits. Molecules colored white and with italic lettering 
have no associated gene expression data. 
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Results 
Multiplex Ligation-dependent Probe Amplification (MLPA) 
 To determine the status of the EGFR gene, in regard to its copy number and possible 
presence of the EGFRvIII mutation, we analyzed 98 cases with previously diagnosed CNS 
tumors with the MLPA Salsa P315 Kit for EGFR. MLPA was theoretically suitable for this task 
because it can be both a qualitative and quantitative method (Schouten et al., 2002). The 
SALSA P315 Kit for EGFR has 28 probes (one for each exon of the gene) and 9 control 
probes for other genomic regions. This kit enabled us to quantify each individual exon in a 
given sample, when compared to a set of normal control samples. The resulting ratios for 
each sample would then allow us to determine if a particular exon is over- or 
underrepresented, and if the complete set had a particular pattern of representation.  
 By MLPA and as show in Table 1 and Figure 4 (page 12), EGFR amplification was 
found in 43% of GBM, 42% of high-grade Oligodendrogliomas (Oligodendrogliomas grades 
IV and III, and Astrocytoma grade IV) and 9% of low-grade Oligodendroglioma 
(Oligodendroglioma grade II) (this is a particular case, in which the only amplification 
detected was also the only case of EGFRvIII detection in the low-grade Oligodendroglioma 
group). EGFRvIII mutation was detected in 8% of GBM, 5% of high-grade Oligodendroglioma 
and 9% of low-grade Oligodendroglioma. EGFR gain was detected in 10% of GBM, 24% of 
high-grade Oligodendroglioma and 9% of low-grade Oligodendroglioma. No change of EGFR 
status was detected in 39% of GBM, 29% of high-grade Oligodendroglioma and 82% of low-
grade Oligodendroglioma. 
 
Table 1. EGFR gene status analysis in CNS Tumors by MLPA. 
Hystological Type EGFR Amplification 
EGFR 
Amplification 
and EGFRvIII 
Mutation 
EGFR Gain No change Total 
Glioblastoma Multiforme 
(GBM) 21 cases (43%) 4 cases (8%) 5 cases (10%) 
19 cases 
(39%) 
49 
cases 
Oligodendroglioma Grades 
IV and III + Astrocytoma 
Grade IV 
16 cases (42%) 2 cases (5%) 9 cases(24%) 11 cases (29%) 
38 
cases 
Oligodendroglioma Grade II 0 cases (0%) 1 case (9%) 1 case (9%) 9 cases (82%) 
11 
cases 
Total 37 cases (38%) 7 cases (7%) 15 cases (15%) 
39 cases 
(40%) 
98 
cases 
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Figure 4. EGFR gene status analysis in CNS Tumors by MLPA. Blue bars represent EGFR Amplification, Orange 
bars represent EGFR Amplification and simultaneous detection of EGFRvIII mutation, Red bars represent EGFR 
Gain and Green bars represent no change in EGFR status. Numbers indicate the number of samples related with 
the particular EGFR status. 
EGFR signaling pathways gene expression analysis 
 To understand how the EGFR signaling pathways behave in GBM, we selected a 
group of 15 samples (previously analyzed by cCGH) that was broad enough to describe the 
most common genetic events in GBM (Table 2, page 13). The first group of samples (cases 
1, 2, 3 ,4 and 5; Group 1) was composed by cases with GBM that were characterized by 
cCGH as having (among other changes) gain of chromosome 7 and amplification of 7p12 
(amp7p12). The second group (cases 6, 7 and 8; Group 2) was composed by cases with 
GBM that were characterized by cCGH as having (among other changes) gain of 
chromosome 7. The third group (cases 9 and 10; Group 3) was composed by one case of 
GBM and another case of AO that were characterized by cCGH as having (among other 
changes) amplification of 8q24. In one case (case 11) we obtained RNA for both the cell line 
and tumor, which allowed us to determine if the EGFR signaling pathway profile was 
maintained between the tumor and the cell line. One case (case 12), was characterized by  
cCGH as having (among other changes) gain of chromosome 7 and amplification in 4q12. 
There were also in our group of samples different individual cell lines derived from primary 
tumors that had unique changes in their cCGH profiles (cases 13, 14 and 15). These 
samples were included to determine if different genomic modifications would produce 
different EGFR signaling pathways profiles. Also, due to sample size limitation, we sought to 
statistically validate our results by comparing them with the publicly available data of Group 1 
(79 cases) and Group 2 (106 cases) tumor types derived from the work of “The Cancer 
Genome Atlas” (TCGA, 2008), of which we used a total of 185 tumor cases. 
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Table 2. Samples used in Gene Expression Analysis. 
Case Type Sex Hystological Type Chromosomal Gains (determined by cCGH) 
1 Tumor F Glioblastoma Multiforme 
Total Gain of Chromosome 7 with Amplification 
of 7p12 
2 Tumor F Glioblastoma Multiforme 
Total Gain of Chromosome 7 with Amplification 
of 7p12 
3 Tumor M Glioblastoma Multiforme 
Total Gain of Chromosome 7 with Amplification 
of 7p12 
4 Tumor F Glioblastoma Multiforme 
Total Gain of Chromosome 7 with Amplification 
of 7p12 
5 Tumor M Glioblastoma Multiforme 
Total Gain of Chromosome 7 with Amplification 
of 7p12 
6 Tumor M Glioblastoma Multiforme Total Gain of Chromosome 7 
7 Tumor M Glioblastoma Multiforme Total Gain of Chromosome 7 
8 Tumor M Glioblastoma Multiforme Total Gain of Chromosome 7 
9 Tumor M Glioblastoma Multiforme DNA Amplification of 8q24.2 
10 Tumor M Anaplastic Oligodendroglioma DNA Amplification of 8q24.1 
11 Cell Line M Anaplastic Ganglioglioma 
Total Gain of Chromosome 7 
Tumor Total Gain of Chromosome 7 
12 Tumor M Glioblastoma Multiforme 
Total Gain of Chromosome 7 and Amplification 
of 4q12 
13 Cell Line M Glioblastoma Multiforme Total Gain of Chromosome 7 
14 Cell Line F Glioblastoma Multiforme DNA Amplification of 3q, 4p, 18q and Xq 
15 Cell Line F Glioblastoma Multiforme 
Total Gain of Chromosome 7 and Amplification 
of 3q, 4q and 12q 
Note: In one case (11), RNA for tumor and cell line was available for microarray analysis.  
 
 
To understand how the molecules in the EGFR signaling pathways were expressed in 
our samples, we used Affymetrix’s GeneChip® HuGene 1.0 ST gene expression microarrays 
that allow us to determine the expression values of 28,869 genes. Having the data for each 
individual sample, we then compared the subgroups with the normal brain cerebral cortex 
control. This comparison was made with Partek Genomics Suite’s ANOVA, which made it 
possible to generate gene expression Ratios and FC between the subgroups and the normal 
control. Gene lists for each comparison were made, and only genes with a FC over 2 or 
below -2 were selected for further analysis. Gene lists filtered by FC were then inputted into 
the IPA software, generating networks and canonical pathways, of which the EGFR Signaling 
pathway was of particular interest (Table 3, page 14). 
 
 
 
 
Gene Expression Alterations in Central Nervous System Neoplasms With EGFR  Amplification 
 
Marco Moedas, FCUL 2009  14 
 
Table 3. EGFR Canonical Pathway in the various samples groups (Ingenuity Pathway Analysis). 
Cases Genes Overexpressed (FC ≥ 2) 
Genes Underexpressed 
(FC ≤ -2) 
Genes with no Change in 
Expression 
(-2 ≤ FC ≤ 2) 
Group 1 vs N 7/48(14.5%) 4/48 (8.4%) 37/46 (77.1%) 
Case 3 (EGFRvIII vs 
N) 8/48 (16.6%) 4/48 (8.4%) 36/48 (75%) 
Group 2 vs N 7/48 (14.5%) 6/48 (12.5%) 35/46 (73%) 
Group 1 vs Group 2 2/48 (4%) 0/48 (0%) 46/48 (96%) 
Group 1 vs Group 2 
(TCGA data) 1/48 (2%) 0/48 (0%) 47/48 (98%) 
Group 3 vs N 5/48 (10.5%) 5/48 (10.5%) 38/48 (79%) 
Case 11 - Cell Line 
vs N 6/48 (12.5%) 11/48 (23%) 31/48 (64.5%) 
Case 11 – Tumor vs 
N 5/48 (10.5%) 7/48 (14.5%) 36/48 (75%) 
Case 12 vs N 7/48 (14.5%) 8/48 (16.6%) 33/48 (68.9%) 
Case 13 vs N 6/48 (12.5%) 11/48 (23%) 31/48 (64.5%) 
Case 14 vs N 5/48 (10.5%) 13/48 (27%) 30/48 (62.5%) 
Case 15 vs N 8/48 (16.6%) 11/48 (23%) 29/48 (60.4%) 
N = Normal Cerebral Cortex 
 
Tumors with Gain of Chromosome 7 and Amplification of 7p12 vs N 
When comparing expression data of Group 1 vs N in our series  as depicted in Figure 
5 (page 15) and Table 4 (page 16), in what concerns EGFR canonical pathway, several 
findings drew our attention. The most striking was the degree of overexpression of the EGFR 
gene with a fold-change of 10.66 over the normal control (p-value 0.111). Analysis of EGFR 
signaling revealed different profiles in the various intracellular transducer branches. 
Accordingly, in the MAPK signaling cascade, we verified that transducers molecules did not 
have a distinctive uniform profile of gene expression. That is, molecules in this pathway were 
either underexpressed (e.g. MKK4, FC = -3.07), had no change in expression (e.g. hRas, FC 
= -1.07) or were overexpressed (e.g. MEKK1, FC = 2.27) without an evident pattern that 
could indicate a preferential activation of this pathway branch. In the PIP signaling pathway 
we saw no changes in expression, except for the underexpression of one of the genes that 
constitute the ITPR (e.g. ITPR1, FC = -5.54).  
In the STAT signaling pathway we saw an overexpression of both STAT3 and STAT1 
genes (with an average FC of 2.1 for STAT1 and STAT3 when compared with normal 
cerebral cortex, with a p-value of 0.168 for STAT1 and 0.015 for STAT3). Although through 
analysis of figure 5 there is seemingly no direct interaction between the STAT proteins and 
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the EGFR protein, it is known that EGFR is able to directly activate these proteins (Coffer et 
al., 1995) without need of interaction with the JAK proteins.   
The combined results from the three different EGFR activated signaling transducers 
branches lead us to suggest that there is an apparent genetic preference for EGFR signaling 
to proceed through the STAT signaling pathway in this group of cases. 
In one case, EGFRvIII mutation was detected by the MLPA technique (case 3), and 
we also proceeded to analysis of the EGFR signaling pathway in this case. In similarity with 
other cases with amp7p12, an apparent genetic expression preference for EGFR signaling to 
proceed through STAT signaling was also found (Supplementary Figure S6 and Table S1). 
Although the IPA canonical pathways were very useful in ascertaining if there was a 
genetic preference for signaling in GBM with amp7p12, it was clear that the IPA canonical 
pathway for EGFR signaling was incomplete. We therefore used a more detailed EGFR 
pathway (Oda et al., 2005) depicted in Figure 6 (page 16). The results obtained were similar 
to those obtained with the IPA pathway (Figure 5), with evidence of a genetic preference for 
EGFR signaling to proceed through the STAT proteins becoming apparent. 
 
 
 
 
 
 
 
 
Figure 5. IPA EGFR Canonical Pathway in Tumors with Gain of Chromosome 7 and Amplification in the 
Chromosomal Region 7p12 vs Normal Cerebral Cortex. Molecules colored red are overexpressed, molecules 
colored green are underexpressed, molecules colored grey have no change in gene expression and molecules 
colored white have no information in regard to gene expression.  
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Table 4. EGFR Canonical Pathway characterization in Group 1 vs Normal Cerebral Cortex. 
Cases Genes Overexpressed (FC ≥ 2) Genes Underexpressed (FC ≤ -2) 
Genes with no Change 
in Expression 
(-2 ≤ FC ≤ 2) 
Group 1 
vs N 
7/48 
(14.5%) 
c-Fos, c-Jun, EGFR, 
MEKK1, SHC, STAT1, 
STAT3 
4/48 
(8.4%) 
IPTR1, JNK1, MKK4, 
PIK3CB 37/48 (77.1%) 
 
 
 
 
 
 
Figure 6. EGFR Pathway (adapted from Oda et al., 2005) in Tumors with Gain of Chromosome 7 and 
Amplification in the Chromosomal Region 7p12 (Group 1) vs Normal Cerebral Cortex. Molecules colored red are 
overexpressed, molecules colored green are underexpressed, molecules colored white have no change in gene 
expression and molecules colored white with italic lettering have no data of expression  Trapezoids represent 
receptor tyrosine kinases, rectangles represent generic proteins, circles represent simple molecules. 
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Tumors with Gain of Chromosome 7 vs N 
 When comparing Group 2 vs N we could observe that the EGFR canonical pathway 
depicted in Figure 7 and Table 5 (page 18) was very similar to the one obtained for the 
previous cases (Group 1). The most striking difference between them was the degree of 
overexpression of the EGFR gene, which was 2.4 times more expressed in these samples 
than in the normal cerebral cortex control (p-value = 0.108). In regard to the signaling 
pathway branches, results were similar of those obtained in Group 1 vs N, where no 
distinctive pattern of gene expression in MAPK or PIP signaling pathways was observed. 
Overexpression of STAT, more specifically, the STAT3 gene with a 2.3 fold-change over the 
normal cerebral cortex control (p-value = 0.065) was a distinctive feature in this cases. 
 As in the previous samples group, a more detailed EGFR signaling pathway was built  
as depicted in Figure 8 (page 18) and again, the results were similar of those obtained with 
the IPA EGF canonical pathway. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7. IPA EGFR Canonical Pathway in Tumors with Gain of Chromosome 7 vs Normal Cerebral Cortex. 
Molecules colored red are overexpressed, molecules colored green are underexpressed, molecules colored grey 
have no change in gene expression and molecules colored white have no information in regard to gene 
expression.  
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Table 5. EGFR Canonical Pathway characterization in Group 2 vs Normal Cerebral Cortex. 
Cases Genes Overexpressed (FC ≥ 2) Genes Underexpressed (FC ≤ -2) 
Genes with no Change 
in Expression 
(-2 ≤ FC ≤ 2) 
Group 2 
vs N 
7/48 
(14.5%) 
c-Fos, c-Jun, EGFR, 
ITPR3, PIK3CG, SHC, 
STAT3 
6/48 
(12.5%) 
IPTR1, JNK1, MEK1, 
MKK4, PIK3CB, 
PIK3C2B 
35/48 (73%) 
 
 
 
 
 
 
Figure 8. EGFR Pathway (adapted from Oda et al, 2005) in Tumors with Gain of Chromosome 7 (Group 2) vs 
Normal Cerebral Cortex. Molecules colored red are overexpressed, molecules colored green are underexpressed, 
molecules colored white have no change in gene expression and molecules colored white with italic lettering have 
no data of expression. Trapezoids represent receptor tyrosine kinases, rectangles represent generic proteins, 
circles represent simple molecules. 
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Tumors with Gain of Chromosome 7 and Amplification in 7p12 vs Tumors with Gain of 
Chromosome 7 
Comparison between Group 1 and Group 2 of our series as depicted in Figure 9 and 
Table 6, revealed that there were no significant differences between the gene expression of 
most of the individual molecules in the EGFR mediated signaling pathways between these 
two groups. However, there was a striking difference between them in the overexpression of 
the EGFR gene, which was 5.42 fold overexpressed (p-value of 0.0387), what can be related 
to the lack of amplification of the EGFR gene in Group 2 samples. 
 
 
 
 
 
 
Table 6. EGFR Canonical Pathway characterization in Group 1 vs Group 2. 
Cases Genes Overexpressed (FC ≥ 2) Genes Underexpressed (FC ≤ -2) 
Genes with no Change 
in Expression 
(-2 ≤ FC ≤ 2) 
Group 1 
vs Group 
2 
2/48 (4%) EGFR, PIK3C2B 0/48 (0%) - 46/48 (94%) 
 
Figure 9. IPA EGFR Canonical Pathway in Tumors with Gain of Chromosome 7 and Amplification in 7p12 vs 
Tumors with Gain of Chromosome 7. Molecules colored red are overexpressed, molecules colored green are 
underexpressed, molecules colored grey have no change in gene expression and molecules colored white have no 
information in regard to gene expression.  
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Tumors with Gain of Chromosome 7 and Amplification in 7p12 vs Tumors with Gain of 
Chromosome 7 (TCGA data) 
Statistical validation of our results was performed by comparing them with the publicly 
available gene expression array data of GBM derived from the work of “The Cancer Genome 
Atlas” (TCGA) consortium (http://cancergenome.nih.gov/dataportal/data/about/). TCGA used 
a different microarray set (GeneChip® Human Genome U133 Plus 2.0 Array from Affymetrix) 
to analyze gene expression in 79 cases of GBM with amp7p12 and 106 cases of GBM with 
gain of chromosome 7. Data was analyzed with the same protocol used in our series of data 
(Partek one-way ANOVA analysis with FC filtering, followed by Ingenuity Pathway Analysis). 
The EGFR canonical pathway retrieved from IPA depicted in Figure 10 and Table 7 (page 
21) markedly resembled the one obtained with our data series. Concurrently, using the 
TCGA database analysis evidenced that the most significant difference between GBM with 
amp7p12 and GBM with gain of chromosome 7 was the expression level of the EGFR gene. 
This gene presented an average 13.29 fold-change (p-value = 1.73E-34) in GBM with 
amp7p12 over GBM with gain of chromosome 7 in the TCGA data series. 
 
 
 
 
 
 
 
 
 
Figure 10. IPA EGF Canonical Pathway in Tumors with Gain of Chromosome 7 and Amplification in 7p12 vs 
Tumors with Gain of Chromosome 7 (TCGA data). Molecules colored red are overexpressed, molecules colored 
green are underexpressed, molecules colored grey have no change in gene expression and molecules colored 
white have no information in regard to gene expression.  
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Table 7. EGFR Canonical Pathway characterization in Group 1 vs Group 2 (TCGA data). 
Cases Genes Overexpressed (FC ≥ 2) Genes Underexpressed (FC ≤ -2) 
Genes with no Change 
in Expression 
(-2 ≤ FC ≤ 2) 
Group 1 
vs Group 
2 (TCGA 
data) 
1/48 (2%) EGFR 0/48 (0%) - 47/48 (98%) 
Tumors with Amplification in 8q24 vs N 
Analysis of Group 3 vs N data revealed a different pattern for the EGFR signaling 
pathway branches as depicted in Figure 11 and Table 8 (page 22). Although overexpression 
of the EGFR gene was evident with a 2.3 fold-change over the normal cerebral cortex control 
in this sample group, there was no ascertainable genetic preference for any of the signaling 
pathways, in contrast with previous sample groups (Groups 1 and 2) in which a genetic 
preference for STAT signaling was apparent. 
In these cases, STAT3 gene had a FC of 1.7 over the normal control, which falls 
below our selected limit. This result was also evident in the more detailed EGFR signaling 
pathway (Supplementary Figure S7). 
Data analysis of these samples also revealed a striking overexpression of the c-Myc 
gene (which is amplified in these samples), with a FC of 6.16. Recently c-Myc 
overexpression was reported in glioma (Faria et al., 2008) and it has been implicated as a 
key gene in gliomagenesis (Lassman et al., 2004; Bredel et al., 2005) and maintenance of 
glioma cancer stem cells (Wang et al., 2008).  
 
 
Figure 11. IPA EGFR Canonical Pathway in Tumors with Amplification in 8q24 vs Normal Cerebral Cortex. 
Molecules colored red are overexpressed, molecules colored green are underexpressed, molecules colored grey 
have no change in gene expression and molecules colored white have no information in regard to gene expression.  
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Table 8. EGFR Canonical Pathway characterization in Group 3 vs Normal Cerebral Cortex. 
Cases Genes Overexpressed (FC ≥ 2) Genes Underexpressed (FC ≤ -2) 
Genes with no Change 
in Expression 
(-2 ≤ FC ≤ 2) 
Group 3 
vs N 
5/48 
(10.5%) 
c-Fos, c-Jun, EGFR, 
MEKK1, STAT1 
5/48 
(10.5%) 
ITPR1, MEK1, MKK4 
PIK3CB, PIK3C2B 38/48 (79%) 
 
Anaplastic Ganglioglioma Cell Line and Tumor vs N 
Another goal of this work was to determine if cell lines derived from primary tumors 
maintained the EGFR signaling pattern of the original tumors. For one of the cases (case 11) 
of our group of samples, RNA quality and quantity for both tumor and cell line were adequate 
for microarray analysis, enabling us to investigate the EGFR signaling pathway in both 
samples. As depicted in Figure 12 and Table 9 (cell line) and Figure 13 and Table 10 (tumor, 
page 23), the EGFR signaling pathway is essentially equal in both cell line and tumor, with, 
again, an apparent preference toward STAT signaling, in a very similar result to those of the 
other samples analyzed. The comparison of the cell line sample vs the tumor sample yielded 
a totally unchanged EGFR pathway (not shown). The more detailed EGFR signaling pathway 
confirmed these results (not shown). 
 
 
 
T 
 
 
Figure 12. IPA EGFR Canonical Pathway in a Tumor Cell Line with derived from an Anaplastic Ganglioglioma of 
case 11 vs Normal Cerebral Cortex. Molecules colored red are overexpressed, molecules colored green are 
underexpressed, molecules colored grey have no change in gene expression and molecules colored white have no 
information in regard to gene expression.  
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Table 9. EGFR Canonical Pathway characterization in Case 11 (Cell Line) vs Normal Cerebral Cortex. 
Cases Genes Overexpressed (FC ≥ 2) Genes Underexpressed (FC ≤ -2) 
Genes with no Change 
in Expression 
(-2 ≤ FC ≤ 2) 
Case 1 – 
Cell Line 
vs N  
6/48 
(12.5%) 
c-Jun, EGF, ITPR3, 
SHC1, STAT1, STAT3 
11/48 
(23%) 
ERK 3,ITPR1, ITPR2, 
JNK1, MEK1, MKK4, 
PIK3CB, PIK3C2B, 
PIK3C3, PIK3R1, 
RasGAP, 
31/48 (64.5%) 
 
 
 
 
T 
 
Table 10. EGFR Canonical Pathway characterization in Case 11 (Tumor) vs Normal Cerebral Cortex. 
Cases Genes Overexpressed (FC ≥ 2) Genes Underexpressed (FC ≤ -2) 
Genes with no Change 
in Expression 
(-2 ≤ FC ≤ 2) 
Case 11 - 
Tumor vs 
N  
5/48 
(10.5%) 
c-Fos, c-Jun, PIK3CG, 
PIK3R5, STAT3 
7/48 
(14.5%) 
ERK3, ITPR1, JNK1, 
MEK1, MKK4, 
PIK3C2B, PIK3CB 
36/48 (75%) 
  
Tumor with Gain of Chromosome 7 and Amplification in 4q12 vs N 
The comparison of case 12 vs normal cerebral cortex, as represented in Figure 14 
and Table 11 (page 24), revealed an apparent preference towards STAT signaling, as in our 
previous results for Groups 1 and 2. In this case, STAT3 gene had a 2.5 fold overexpression 
over the normal control. Data analysis also revealed overexpression of PDGFRα (whose 
Figure 13. IPA EGFR Canonical Pathway in an Anaplastic Ganglioglioma of case 11, with gain of chromosome 7 
vs Normal Cerebral Cortex. Molecules colored red are overexpressed, molecules colored green are 
underexpressed, molecules colored grey have no change in gene expression and molecules colored white have 
no information in regard to gene expression.  
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locus is amplified in this sample). This protein is an indirect activator of STAT3 (activation is 
mediated by JAK) (Vignais et al., 1999) and in our samples had a 7.85 fold gene 
overexpression over the normal control. This event may constitute an alternative activating 
pathway for STAT3 in this sample. Results were confirmed by the more detailed EGFR 
signaling pathway (not shown). 
 
 
 
 
 
Table 11. EGFR Canonical Pathway characterization in Case 12 vs Normal Cerebral Cortex. 
Cases Genes Overexpressed (FC ≥ 2) Genes Underexpressed (FC ≤ -2) 
Genes with no Change 
in Expression 
(-2 ≤ FC ≤ 2) 
Case 12 
vs N  
7/48 
(14.5%) 
c-Fos, c-Jun, EGFR, 
PIK3C2G, PIK3CG, 
PIK3R5, STAT3 
8/48 
(16.6%) 
JNK1, ITPR1, MEK1, 
MKK4, JNK1, PIK3C3, 
PIK3C2B, PIK3CB, 
RasGAP 
33/48 (68.9%) 
 
Other Cases vs N 
 In other comparative analysis using samples that represent unique cell lines derived 
from primary GBM (depicted in Supplementary Figures S8, S9 and S10 and Tables S2, S3 
and S4), the EGFR signaling pathway continued to reveal an apparent preference towards 
STAT signaling independently of the cytogenetic changes the cell lines possess, what was 
also confirmed by the more detailed EGFR signaling pathways (not shown).  
 
Figure 14. IPA EGFR Canonical Pathway in a Tumor with Gain of Chromosome 7 and Amplification in 4q12 (case 
12) vs Normal Cerebral Cortex. Molecules colored red are overexpressed, molecules colored green are 
underexpressed, molecules colored grey have no change in gene expression and molecules colored white have 
no information in regard to gene expression.  
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Discussion 
EGFRvIII mutation detection by MLPA 
 The results of our MLPA experiments were different from those previously 
documented in the Portuguese population (Viana-Pereira et al., 2008) in regard to the 
EGFRvIII mutation prevalence. In their work, Viana-Pereira et al. studied the incidence of 
EGFR overexpression, amplification and EGFRvIII mutation in a Portuguese group of high-
grade gliomas. In this group’s cases EGFR amplification was found in 54% of GBM and 67% 
of Anaplastic Oligodendrogliomas (AO) [versus 43% and 42% (AO are similar to high-grade 
Oligodendrogliomas) respectively, in our cases]. EGFRvIII mutation was detected in 22% of 
GBM and 8% of AO (versus 8% and 5% respectively, in our cases). 
The difference between our results and Viana-Pereira’s group may be explained by 
the different methods used (Viana-Pereira et al. used immunohistochemistry in their attempt 
to identify the prevalence of EGFRvIII mutation). To our knowledge, no work has been 
published, using the MLPA kit P315 for EGFR, for investigation of EGFRvIII prevalence in 
any population.  
 To address the issue of different prevalence of the EGFRvIII mutation between our 
technique and Viana-Pereira’s, we propose that a third different technique should be used to 
evaluate the mutation’s prevalence in the same group of individuals, mainly a mRNA based 
evaluation like the one proposed by Mellinghoff et al. (Mellinghoff et al., 2005) and 
Yoshimoto et al. (Yoshimoto et al., 2008). 
What our results also reflect is that amplification of EGFR is a current event in high-
grade gliomas (both GBM and high-grade Oligodendrogliomas) (Figure 4, page 12) being 
relatively rare in low-grade gliomas, as previously stated by Ohgaki et al. (Ohgaki et al., 
2005). 
 
EGFR Pathway Analysis in Glioma 
 Some of the hallmarks of high-grade gliomas are total gain of chromosome 7, 
amplification of the EGFR gene and total loss of chromosome 10 or partial loss of 
chromosome arm 10q (Ohgaki et al., 2007). EGFR signaling can be deregulated by these 
two events, at the activation level by EGFR, and at the inhibition level by PTEN (located in 
10q23). EGFR signaling deregulation has been confirmed as a key event in high-grade 
gliomas (TCGA, 2008). With this work, we sought to understand the pattern of expression of 
the genes that compose the EGFR pathway and if there was any preference for a particular 
“branch” of the pathway. 
  In the majority of our samples, the STAT3 and STAT1 genes have, on average, a 
two-fold increment over the normal control. On the other hand, genes in the PIP and MAPK 
branches of the EGFR signaling pathway have different levels of expression, that do not 
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clearly indicate any type of preference toward one or the other. In the PIP pathway there was 
no ascertainable change in its component’s gene expression in the majority of our samples, 
what lead us to believe that there was no particular preference for EGFR signaling to 
proceed through PIP signaling. In what concerns the MAPK cascade in the EGFR signaling, 
there was an apparent antagonistic level of expression in its transducer molecules. As 
depicted in Figure 5 (page 15 of the Results section), overexpression (e.g. MEKK1), 
underexpression (e.g. MKK4) and no change in expression (e.g. MKK7) coexisted in the 
same branch of the pathway. This seemingly incompatible gene expression between the 
constituents of the MAPK cascade may lead to a decreased signaling ability by this pathway, 
what lead us to believe that, like for PIP signaling, there was no particular preference for 
EGFR signaling to proceed through the MAPK cascade. 
Of the three possible EGFR transducer intracellular signaling cascades (PIP, MAPK 
and STAT), we could recognize that gene expression changes support a preferential 
signaling through STAT1/3. 
However, in one sample group (Group 3, amp8q24), we did not observe this event. 
As depicted in Figure 11 and Table 8 (pages 21 and 22 of the Results section), the Group 3 
vs N analysis did not show a clear preference for STAT3, but data analysis of gene 
expression revealed an increased expression of the c-Myc gene. In the comparisons of 
Group 1 vs N and Group 2 vs N, c-Myc overexpression was also evident, with a median FC 
of 4.05.  It is known that STAT3 is a mediator of c-Myc transcription (Dauer et al., 2005) and 
inhibition of STAT3 in glioma cells leads to decreased expression of c-Myc (Gu et al., 2008). 
Thus, the STAT3 signaling preference revealed in Group 1 and 2 cases can be interpreted 
as a glioma cell strategy to induce increased expression of c-Myc when no other possibility 
(like amplification of the gene locus) exists. If so, amplification of the c-Myc locus, which 
occurs in Group 3, would relieve selective pressure for EGFR signaling to proceed through 
STAT3, leading to decreased overexpression of this gene. This hypothesis could therefore 
explain why STAT3 signaling preference is not so evident in Group 3 cases when compared 
with Group 1 and 2 cases. 
 STAT3 activation has been encountered in roughly 51% of GBM (Abou-Ghazal et al., 
2008), and has been identified as a key regulator of both immune suppression and 
tumorigenesis. STAT3 activity in natural killer cells and neutrophils leads to decrease of their 
citotoxic activity. In dendritic cells STAT3 reduces the expression of MHC II, CD80, CD86 
and IL12, which renders these cells unable to stimulate T cells and generate antitumor 
immune responses (Kortyleswki et al., 2008). STAT3 participation in tumorigenesis lies in its 
ability to induce transcription of several genes involved in preventing apoptosis and 
enhancing proliferation, angiogenesis, invasion and metastasis (Dauer et al., 2005; Abou-
Ghazal et al., 2008).  
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 As previously stated, the STAT3 protein is a direct target of EGFR-mediated 
phosphorylation, what occurs when STAT3 binds phosphorylated residues in the C-terminus 
of the EGFR protein (Y1068 and Y1086) (Xia et al., 2002), which in turn phosphorylates the 
Tyrosine 705 residue of STAT3, leading to STAT3 homo- or heterodimerization, nuclear 
translocation and gene activation, making this the most straight-forward pathway for EGFR 
signaling. STAT3 activity is regulated by various proteins, mainly PIAS, SOCS and protein 
phosphatases like PTPRD. In the majority of our samples, the genes encoding these proteins 
are either underexpressed or have no change in gene expression. The PTPRD gene for 
instance has an average five-fold gene expression reduction in Group 1 and 2 samples vs N.  
 Knowing the importance of STAT3 activation in glioma, several attempts at promoting 
apoptosis and decreased proliferation of glioma by inhibition of STAT3 activity have been 
made. 
One of the first attempts of inhibiting STAT3 was made by Konnikova et al. 
(Konnikova et al., 2003) with siRNA. In this work, Konnikova et al. inhibited STAT3 in 
astrocytoma cell lines and normal human astrocytes (NHA) and observed a decreased 
viability and induction of apoptosis in the astrocytoma cell lines but not in the NHA, proposing 
siRNA should be used as a possible therapy.  
Another effort, by Shao et al. (Shao et al., 2003), used phosphopeptides in squamous 
carcinoma cells. Phosphopeptides, mimicking the phosphorylated residues of EGFR where 
STAT3 binds for activation (Y1068 and 1086), resulted in a destabilization of STAT3 
homodimers, and thus, lead to a decrease of STAT3-DNA binding and cell proliferation.  
One attempt at inhibiting STAT3 by blocking its capacity to bind DNA was made by 
Gu et al. (Gu et al., 2008). Gu et al. used decoy oligonucleotides (ODN) mimicking STAT3 
specific cis-elements in two glioma cell lines. These ODN blocked STAT3 signaling and 
decreased its capacity to mediate transcription of several genes including c-Myc, Cyclin D1 
and Bcl-xl, resulting in decreased cell proliferation by inducing of apoptosis and cell-cycle 
arrest.  
Use of small molecule inhibitors of STAT3 was proposed by Fuh et al. (Fuh et al., 
2009). Fuh et al. used LLL-3, a polyphenol that binds the SH2 domain of STAT3 (the binding 
domain), leading to a decreased ability for STAT3 to dimerize. Applying LLL-3 to various 
glioma cell lines led to the inhibition of STAT3-dependent transcription and to induction of 
apoptosis in the cell lines. In mice with injection of GBM cell lines, the use of LLL-3 increased 
viability from 16 days to 28.5 days.  
Li et al. (Li et al., 2009) used a strategy based upon delivery of a lentiviral vector with 
a shRNA specific for STAT3, to induce knockdown of STAT3 expression in GBM cell lines. 
STAT3 inhibition with this approach led to suppression of growth and increase in apoptosis in 
the cell lines and also an increase in differentiation of some cells. 
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Conclusion: 
 Deregulation of the EGFR signaling pathway is one of the most important features of 
GBM. When deregulated, this pathway confers upon the GBM cells an increased ability to 
proliferate and evade both apoptosis and immune responses from the host. Suppressing the 
activity of this pathway should, in theory, lead to a decrease in some of these abilities, and 
hence, to a decrease in tumor mass and an increase in survival of the host. Efforts in the 
targeting of this pathway have been made, mostly through the inhibition of the EGFR protein. 
Although some progress has been made, progression free survival of GBM patients still 
remains dismal. This probably occurs because EGFR shares most of its pathways with other 
RTKs and non-RTKs, giving the glioma cells the ability to bypass inhibition of EGFR, through 
activation of its core signaling pathways via other RTKs and non-RTKs. Clearly, another 
target, downstream from activators like EGFR, must be selected to enable blockage of GBM 
core pathways. Several attempts at targeting key components of the PIP and MAPK 
signaling cascade have been made in this regard, but median survival time remains dismal.  
Our work reveals STAT3 as another potential molecule that can fit this description. STAT3 
overexpression and activation have been proven in GBM, but, to our knowledge, no work has 
been published on the preferential 
activation of the STAT3 pathway in 
GBM (Figure 15).  
 We can look at STAT3 as a 
“molecular hub” because it is activated 
by various RTKs and non-RTKs, and it 
can lead to increased transcription of 
several genes related to proliferation, 
immune evasion and inhibition of 
apoptosis. In theory, inhibition of the 
signaling pathways at this level should 
overcome the obstacles found in the 
inhibition of EGFR. And in fact, some 
recent work on inhibition of STAT3 in 
glioma cells has yielded promising results, although, to our knowledge, no clinical trials 
involving any of the strategies mentioned in the discussion are ongoing. 
 We are aware that sample size is a limitation of our work, so we propose as a future 
work to scale-up our results, with different approaches directed at STAT3: evaluation of the 
mRNA levels through real-time RT-PCR and validation of STAT3 activation by evaluation of 
Tyrosine 705 Phosphorylated STAT3 and Tyrosine 1068 Phosphorylated EGFR presence 
through immunohistochemistry in a larger set of samples. 
Figure 15. EGFR Signaling pathway model in GBM. 
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Figure S1. Simplified Overview of the cCGH protocol (in http://www.currentprotocols.com/protocol/hg0406). 
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Figure S2. Simplified Overview of the MLPA protocol (in http://www.mrc-holland.com/). 
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Figure S3. Simplified Overview of the GeneChip Microarray protocol (adapted from the GeneChip Whole 
Transcript Sense Target Labelling Assay Technical Manual, Affymetrix). 
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Figure S4. Network shapes in 
IPA (in IPA Help Manual). 
Figure S5. Relationship types in 
IPA (in IPA Help Manual). 
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Table S1. EGFR Canonical Pathway characterization in Case 3 vs Normal Cerebral Cortex. 
Cases Genes Overexpressed  (FC ≥ 2) Genes Underexpressed (FC ≤ -2) 
Genes with no Change 
in Expression 
(-2 ≤ FC ≤ 2) 
Case 3 
vs N  
8/48 
(16.6%) 
c-Fos, c-Jun, EGF, 
EGFR, ITPR2, 
MEKK1, PIK3C2B, 
STAT3 
4/48 
(8.4%) 
JNK1, ITPR1, MKK4, 
PIK3CB 36/48 (75%) 
 
Figure S6. IPA EGFR Canonical Pathway in a Tumor (case 3) with Gain of Chromosome 7, Amplification in 7p12 
and EGFRvIII mutation vs Normal Cerebral Cortex. Molecules colored red are overexpressed, molecules colored 
green are underexpressed, molecules colored grey have no change in gene expression and molecules colored 
white have no information in regard to gene expression. 
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Figure S7. EGFR Pathway (adapted from Oda et al, 2005(ref.10)) in Tumors with Amplification in 8q24 (Group 3) 
vs Normal Cerebral Cortex. Molecules colored red are overexpressed, molecules colored green are 
underexpressed, molecules colored white have no change in gene expression and molecules colored white with 
italic lettering have no data of expression. Trapezoids represent receptor tyrosine kinases, rectangles represent 
generic proteins, circles represent simple molecules. 
 
 
Gene Expression Alterations in Central Nervous System Neoplasms With EGFR  Amplification 
    
 
  SVII 
 
 
 
  
 
 
 
Table S2. EGFR Canonical Pathway characterization in Case 13 vs Normal Cerebral Cortex. 
Cases Genes Overexpressed  (FC ≥ 2) Genes Underexpressed (FC ≤ -2) 
Genes with no Change 
in Expression 
(-2 ≤ FC ≤ 2) 
Case 13 
vs N  
6/48 
(12.5%) 
EGF, EGFR, ITPR3, 
MEKK1, SHC1, 
STAT3 
11/48 
(23%) 
c-Fos, ERK2, ITPR1, 
ITPR2, JNK1, MEK1, 
MKK4, PIK3C2B, 
PIK3CB, PIK3R1, SOS2 
31/48 (64.5%) 
 
 
Figure S8. IPA EGFR Canonical Pathway in a Tumor Cell Line with Gain of Chromosomes 7 (case 13) vs Normal 
Cerebral Cortex. Molecules colored red are overexpressed, molecules colored green are underexpressed, 
molecules colored grey have no change in gene expression and molecules colored white have no information in 
regard to gene expression.  
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Table S3. EGFR Canonical Pathway characterization in Case 14 vs Normal Cerebral Cortex. 
Cases Genes Overexpressed  (FC ≥ 2) Genes Underexpressed (FC ≤ -2) 
Genes with no Change 
in Expression 
(-2 ≤ FC ≤ 2) 
Case 14 
vs N  
5/48 
(10.5%) 
c-Jun, ITPR3, MEKK1, 
SHC1, STAT3 
13/48 
(27%) 
EGFR, ERK2, ITPR1, 
ITPR2, JNK1, MKK4, 
PIK3C2A, PIK3CA, 
PIK3CB, PIK3R1, PKCα, 
RasGAP, SOS1 
30/48 (62.5%) 
 
Figure S9. IPA EGFR Canonical Pathway in a Tumor Cell Line with Amplification in 3q, 4p, 18q and Xq (case 14) 
vs Normal Cerebral Cortex. Molecules colored red are overexpressed, molecules colored green are 
underexpressed, molecules colored grey have no change in gene expression and molecules colored white have 
no information in regard to gene expression.  
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Table S4. EGFR Canonical Pathway characterization in Case 15 vs Normal Cerebral Cortex. 
Cases Genes Overexpressed (FC ≥ 2) Genes Underexpressed (FC ≤ -2) 
Genes with no Change 
in Expression 
(-2 ≤ FC ≤ 2) 
Case 15 
vs N  
8/48 
(16.6%) 
c-Jun, EGF, ERK5, 
ITPR3, PIK3CA, 
PIK3R2, SHC1, STAT3 
11/48 
(23%) 
ERK2, ERK3, ITPR1, 
JNK1, MEK1, MKK4, 
PIK3C3, PIK3C2B, 
PIK3CB, PIK3R1, 
RasGAP 
29/48 (60.4%) 
 
 
Figure S10. IPA EGFR Canonical Pathway in a Tumor Cell Line with Gain of Chromosome 7 and Amplification in 
3q, 4q and 12q (case 15) vs Normal Cerebral Cortex. Molecules colored red are overexpressed, molecules colored 
green are underexpressed, molecules colored grey have no change in gene expression and molecules colored 
white have no information in regard to gene expression.  
